Humana (NYSE:HUM) Stock Rating Upgraded by UBS Group

Humana (NYSE:HUMGet Rating) was upgraded by equities researchers at UBS Group from a “neutral” rating to a “buy” rating in a research note issued on Wednesday, The Fly reports.

Several other equities analysts have also weighed in on the stock. BMO Capital Markets cut their target price on shares of Humana from $490.00 to $415.00 in a report on Friday, January 7th. Sanford C. Bernstein decreased their price objective on shares of Humana from $470.00 to $431.00 in a research report on Tuesday, January 11th. Barclays dropped their target price on Humana from $540.00 to $490.00 and set an “overweight” rating on the stock in a research report on Friday, January 7th. The Goldman Sachs Group assumed coverage on Humana in a report on Tuesday, December 14th. They issued a “neutral” rating and a $472.00 price target for the company. Finally, Morgan Stanley lifted their price target on shares of Humana from $410.00 to $436.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 9th. Seven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $482.94.

Shares of Humana stock opened at $449.04 on Wednesday. The stock has a market cap of $56.91 billion, a PE ratio of 19.81, a price-to-earnings-growth ratio of 1.39 and a beta of 0.94. The firm has a fifty day moving average price of $434.16 and a 200 day moving average price of $430.60. Humana has a 1 year low of $351.20 and a 1 year high of $475.44. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.62 and a quick ratio of 1.62.

Humana (NYSE:HUMGet Rating) last released its quarterly earnings data on Wednesday, February 2nd. The insurance provider reported $1.24 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.23 by $0.01. Humana had a return on equity of 17.39% and a net margin of 3.53%. The business had revenue of $21.05 billion during the quarter, compared to analyst estimates of $21.28 billion. During the same quarter last year, the business posted ($2.30) EPS. The company’s revenue was up 10.5% on a year-over-year basis. As a group, equities analysts expect that Humana will post 24.16 EPS for the current year.

Large investors have recently modified their holdings of the business. BlackRock Inc. lifted its position in shares of Humana by 6.6% during the 4th quarter. BlackRock Inc. now owns 11,254,356 shares of the insurance provider’s stock worth $5,220,447,000 after purchasing an additional 693,945 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Humana by 10.7% in the 3rd quarter. Wellington Management Group LLP now owns 6,465,032 shares of the insurance provider’s stock valued at $2,515,867,000 after buying an additional 626,652 shares during the last quarter. State Street Corp raised its stake in Humana by 0.3% during the 4th quarter. State Street Corp now owns 5,726,024 shares of the insurance provider’s stock worth $2,660,025,000 after acquiring an additional 15,994 shares in the last quarter. Capital Research Global Investors lifted its position in Humana by 49.5% in the fourth quarter. Capital Research Global Investors now owns 3,872,000 shares of the insurance provider’s stock valued at $1,796,075,000 after acquiring an additional 1,281,466 shares during the last quarter. Finally, Capital International Investors boosted its stake in Humana by 0.3% in the fourth quarter. Capital International Investors now owns 3,151,994 shares of the insurance provider’s stock valued at $1,462,210,000 after acquiring an additional 8,127 shares in the last quarter. Institutional investors own 92.96% of the company’s stock.

Humana Company Profile (Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Stories

The Fly logo

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.